Allergan PLC. (NYSE:AGN) – Investment analysts at Gabelli raised their Q3 2017 earnings per share (EPS) estimates for shares of Allergan PLC. in a report issued on Monday. Gabelli analyst K. Kedra now expects that the company will post earnings of $4.16 per share for the quarter, up from their prior forecast of $4.09. Gabelli also issued estimates for Allergan PLC.’s Q4 2017 earnings at $4.72 EPS.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the firm posted $3.35 earnings per share. The business’s revenue was up 8.8% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: “Q3 2017 Earnings Forecast for Allergan PLC. (AGN) Issued By Gabelli” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/16/q3-2017-earnings-forecast-for-allergan-plc-agn-issued-by-gabelli.html.

Several other analysts have also commented on AGN. Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Monday, June 12th. Mizuho lowered their target price on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. UBS AG reiterated a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Citigroup Inc. lifted their target price on shares of Allergan PLC. to $261.00 and gave the company a “buy” rating in a report on Monday, April 24th. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $275.49.

Shares of Allergan PLC. (NYSE AGN) opened at 231.14 on Wednesday. The firm has a market capitalization of $77.27 billion, a PE ratio of 7.04 and a beta of 1.16. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The stock has a 50 day moving average price of $245.03 and a 200-day moving average price of $238.77.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.21%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the company. Israel Discount Bank of New York acquired a new stake in shares of Allergan PLC. during the first quarter valued at about $988,000. Trust Co. of Vermont boosted its stake in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after buying an additional 1,109 shares in the last quarter. Capital Planning Advisors LLC boosted its stake in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after buying an additional 1,625 shares in the last quarter. First Long Island Investors LLC acquired a new stake in shares of Allergan PLC. during the first quarter valued at about $4,826,000. Finally, Rehmann Capital Advisory Group boosted its stake in shares of Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock valued at $425,000 after buying an additional 237 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Earnings History and Estimates for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.